
Entrada Therapeutics (TRDA) P/E Ratio
P/E Ratio as of Jul 2, 2025: 8.99
Average9.27
Median8.99
Minimum8.31
Maximum10.29
8.99
Past Month-1.08 (10.72%)
The P/E ratio for Entrada Therapeutics (TRDA) is 8.99 as of Jul 2, 2025. This represents a increase of 22.31% compared to its 12-month average P/E ratio of 7.35. A higher P/E ratio suggests that investors expect strong future earnings growth, while a lower P/E ratio may indicate a potentially undervalued stock or slowing growth.
Entrada Therapeutics P/E Ratio Formula = Stock Price ÷ Earnings Per Share (EPS)
Entrada Therapeutics’s P/E ratio represents the valuation of the company based on its earnings. It’s calculated by dividing the company’s latest stock price by its diluted earnings per share (EPS) over the past 12 months. The P/E ratio helps investors assess how much they are paying for each dollar of earnings, offering valuable insights when comparing Entrada Therapeutics to industry peers.
Entrada Therapeutics P/E Ratio Formula = Stock Price ÷ Earnings Per Share (EPS)
Entrada Therapeutics’s P/E ratio represents the valuation of the company based on its earnings. It’s calculated by dividing the company’s latest stock price by its diluted earnings per share (EPS) over the past 12 months. The P/E ratio helps investors assess how much they are paying for each dollar of earnings, offering valuable insights when comparing Entrada Therapeutics to industry peers.
Entrada Therapeutics (TRDA) P/E Ratio Insights
See Entrada Therapeutics’s latest P/E ratio, historical trends, and valuation insights with AI-powered fundamental data and custom analysis.
Start investing in Entrada Therapeutics (TRDA)
Order type
Buy in
Order amount
Est. shares
0 shares
Entrada Therapeutics (TRDA) P/E Ratio Historic Data
Date | Stock price | P/E ratio |
---|---|---|
Jul 1, 2025 | $7.11 | 8.80 |
Jun 2, 2025 | $8.14 | 10.07 |
May 1, 2025 | $9.05 | 4.75 |
Apr 1, 2025 | $8.76 | 4.60 |
Mar 3, 2025 | $11.33 | 5.94 |
Feb 3, 2025 | $13.33 | 8.36 |
Jan 2, 2025 | $17.46 | 10.95 |
Entrada Therapeutics (TRDA) End of Year P/E Ratio
Date | P/E ratio | Change |
---|---|---|
2025 | 8.99 | -17.14% |
2024 | 10.85 | -154.20% |
2023 | -20.02 | +318.83% |
2022 | -4.78 | — |
FAQs About Entrada Therapeutics (TRDA) P/E ratio
The latest P/E ratio of Entrada Therapeutics (TRDA) is 8.99, as of Jul 2, 2025. This is calculated based on its current stock price and earnings per share (EPS).
Entrada Therapeutics’s last 12-month average P/E ratio is 7.35, compared to its current P/E ratio of 8.99. This reflects a increase of 22.31%.
Entrada Therapeutics’s current P/E ratio of 8.99 is higher than its last 12-month average P/E of 7.35. A higher P/E can indicate strong future growth expectations, while a lower P/E might suggest undervaluation.
Entrada Therapeutics’s average P/E ratio over the last 3 years is -4.02. Comparing this to the current P/E helps assess recent valuation trends and whether the stock is trading above or below its mid-term historical range.
Entrada Therapeutics’s average P/E ratio over the last 5 years is -2.57. A deviation from this historical average may indicate shifts in growth expectations, profitability, or broader market conditions affecting valuation.